Pneumonitis After Chest Radiation and Immunotherapy: Why the Cause Matters

You finish weeks of radiation to your chest, and your oncologist starts you on immunotherapy. Then a dry cough settles in, or you notice you’re winded walking to the mailbox. It could be nothing. It could also be the start of a serious lung problem that needs fast, correct treatment.

Lung inflammation, called pneumonitis, is a known complication of both chest radiation and immunotherapy. When a patient has had both, working out which one is responsible is one of the harder judgment calls in cancer care. It’s also one of the most important, because the right treatment depends on the answer.

This article explains why the cause matters, what a careful workup looks like, and when a delay or wrong diagnosis may raise legal questions.

What is Pneumonitis

Pneumonitis is inflammation of the lung tissue itself, in the tiny air sacs and the structure around them. It differs from typical bacterial pneumonia, though the symptoms can look alike: a dry cough that won’t quit, shortness of breath, chest discomfort, and sometimes a low-grade fever.

Two cancer treatments are well known for causing it:

• Chest radiation can injure healthy lung tissue in or near the treatment field.

• Checkpoint inhibitors release the brakes on the immune system so it can attack cancer. These include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi), and ipilimumab (Yervoy). Sometimes the freed-up immune system attacks healthy lung as well.

Both are recognized risks listed in drug labels and treatment guidelines. A known complication isn’t automatically negligence. The legal question is whether it was caught and handled the way a careful doctor would have handled it.

Radiation Pneumonitis

Radiation pneumonitis usually appears one to six months after radiation ends, though it can come later. On CT, it often shows hazy areas that line up with where the beam was aimed, though it can spread beyond that.

Risk depends on several factors:

• How much radiation the healthy lung received

• Whether chemotherapy was given at the same time

• Pre-existing lung disease such as COPD or interstitial lung disease

• Age

• Whether the tumor sat in the lower lung

Radiation oncologists plan treatment around dose limits for healthy lung, which is one reason the treatment plan can become relevant later. Standard treatment is corticosteroids such as prednisone, tapered slowly, with oxygen and supportive care as needed.

Immunotherapy Pneumonitis

Checkpoint inhibitor pneumonitis is less predictable. It can appear within weeks of the first dose, many months into treatment, or after treatment has stopped.

A 2018 meta-analysis of 13 randomized trials found pneumonitis in 2.6% of patients on PD-1 or PD-L1 inhibitors, rising to 3.1% in non-small cell lung cancer. Real-world rates are often higher, and combination therapy can raise them further. The authors describe it as rare but potentially life-threatening.

Management follows a severity scale. For mild cases, doctors may pause immunotherapy and watch closely. For moderate or severe cases, they usually stop the drug, start corticosteroids, rule out infection, and add stronger immune-suppressing medication if the patient doesn’t improve. Bronchoscopy, which collects fluid from the airways through a thin camera, may be part of the workup in serious cases.

Why the Two Are Hard to Tell Apart

They look alike. Both cause cough and breathlessness, and both can produce ground-glass changes on CT. Imaging alone often doesn’t settle the question.

Two things make it murkier. First, radiation recall pneumonitis happens when a drug, including a checkpoint inhibitor, triggers inflammation in lung that was irradiated earlier, sometimes long afterward. In that case both treatments are involved.

Second, combining chest radiation with immunotherapy raises the overall rate. In the PACIFIC trial of durvalumab after chemoradiation for stage III non-small cell lung cancer, pneumonitis or radiation pneumonitis occurred in 33.9% of durvalumab patients and 24.8% of those on placebo. Grade 3 or 4 cases occurred in 3.4% and 2.6%. The combination is standard care for many patients and extends lives. But doctors using it should expect lung inflammation as a real possibility and watch for it.

Other Causes That Must Be Ruled Out

Cough and breathlessness in someone with lung cancer, recent radiation, and immunotherapy can come from several other sources:

• Infection, whether bacterial, viral, fungal, or Pneumocystis pneumonia, which is especially dangerous in patients on steroids

• Tumor progression, which can look like inflammation on a scan

• Pulmonary embolism, a blood clot in the lung, which is common in cancer patients

• Heart failure

• Toxicity from other cancer drugs, including some chemotherapies and targeted therapies

Each calls for a different treatment, which is why getting the cause right matters so much.

Why the Diagnosis Changes Treatment

A wrong call is costly in either direction.

Immunotherapy. If the problem is immunotherapy pneumonitis, the drug may need to be paused or stopped for good, which can mean giving up a medication that was working. But stopping effective immunotherapy for what turns out to be something else can hurt cancer outcomes. And continuing it through serious pneumonitis can lead to respiratory failure.

Steroids. High-dose steroids are standard for significant pneumonitis, but they suppress the immune system. If the real problem is an infection that was never ruled out, steroids can make it much worse. Withholding steroids from true pneumonitis, on the assumption that it’s pneumonia, lets inflammation keep damaging the lungs.

The cause also shapes how long to taper steroids, how closely to watch for recurrence, and whether cancer treatment can safely resume.

What a Thorough Workup Looks Like

A careful evaluation doesn’t rest on one scan or one guess. It generally includes:

• A detailed timeline of when radiation ended, when each immunotherapy dose was given, and when symptoms began

• High-resolution CT and oxygen measurements, sometimes with pulmonary function testing

• Cultures and other testing to rule out infection

• Bronchoscopy with lung fluid sampling when the picture is unclear or the patient is worsening

Good care usually means the medical oncologist, radiation oncologist, and a pulmonologist working together. Sometimes it also means a radiologist comparing the scans against the radiation plan. When each specialist looks only at their own piece, connections get missed.

Our page on how lung cancer is diagnosed explains how CT and bronchoscopy are used, and our page on cancer treatments covers radiation and immunotherapy more broadly.

When a Lung Complication Becomes Malpractice in New York

Developing pneumonitis after radiation or immunotherapy is not, by itself, malpractice. A New York claim requires showing that a provider departed from accepted standards of care and that the departure was a substantial factor in causing harm. In these cases, that might look like:

• Ignoring or dismissing reported breathing symptoms

• Delaying imaging, infection testing, or a pulmonology referral

• Starting high-dose steroids without ruling out infection

• Continuing immunotherapy despite clear signs of serious pneumonitis

• Stopping effective immunotherapy based on a wrong diagnosis

• Delaying steroids in a patient who clearly needed them

• Never telling the patient which symptoms to report

• A radiation plan that exposed healthy lung beyond accepted limits, a technical question that requires expert review

Informed consent can matter too. Under Public Health Law § 2805-d, a provider must disclose the risks and alternatives a reasonable practitioner would have disclosed.

To win that claim, the patient must also show that a reasonably prudent person, fully informed, would have declined the treatment. Because these treatments are often life-extending, that part of the claim can be hard to prove.

Causation is usually the central fight. With radiation, immunotherapy, infection, and tumor progression all possible explanations, the defense will often argue the injury was unavoidable or came from a different cause.

New York’s Filing Deadlines

Under CPLR 214-a, most malpractice claims must be filed within two years and six months of the negligent act or omission. Because this is a treatment complication rather than a missed cancer diagnosis, the special discovery rule for failure-to-diagnose-cancer claims generally doesn’t apply. The continuous treatment doctrine can extend the window when a patient keeps receiving care from the same provider for the same condition, which often matters in cancer care.

Claims against public hospitals, including NYC Health + Hospitals, require a notice of claim within 90 days. If a loved one has died, a wrongful death claim generally must be filed within two years of the date of death. We explain those claims in our article on wrongful death after a missed lung cancer.

Talk With a New York Cancer Lawyer

If you or someone you love developed serious lung problems during cancer treatment and you have questions about how it was handled, Porter Law Group can review what happened.

Our New York cancer lawyers work with oncology, radiation oncology, and pulmonology experts to review the timeline, the treatment plan, and the records. For more on lung cancer claims, see our lung cancer malpractice overview and our results in cancer cases.

Call 833-888-LATE, email info@porterlawteam.com, or request a free case evaluation.

Attorney advertising. This article provides general information and is not legal or medical advice. If you have trouble breathing, seek emergency care. Prior results do not guarantee a similar outcome. Filing deadlines depend on the facts of each case.

Frequently Asked Questions

What is the difference between radiation pneumonitis and immunotherapy pneumonitis?

Radiation pneumonitis is lung inflammation from chest radiation, usually appearing one to six months after treatment and often matching the radiation field. Immunotherapy pneumonitis comes from checkpoint inhibitors that rev up the immune system, and it can appear at almost any time. They look similar on CT, so doctors rely on timing, the radiation plan, and testing to tell them apart.

How common is pneumonitis after immunotherapy and chest radiation?

On its own, immunotherapy causes pneumonitis in about 2.6% of trial patients, and 3.1% in non-small cell lung cancer. When it follows chemoradiation, rates are much higher. In the PACIFIC trial of durvalumab, pneumonitis or radiation pneumonitis occurred in 33.9% of patients, though only 3.4% had severe grade 3 or 4 cases.

Why do doctors need to rule out infection before giving steroids for pneumonitis?

High-dose steroids are the standard treatment for significant pneumonitis, but they suppress the immune system. If the real cause is a bacterial, viral, fungal, or Pneumocystis infection, steroids can make it much worse. That’s why a proper workup includes cultures and other infection testing, and sometimes bronchoscopy, before or alongside steroid treatment.

Is pneumonitis after cancer treatment considered medical malpractice?

Not by itself. Pneumonitis is a recognized risk of chest radiation and immunotherapy. It may become malpractice if a provider ignored breathing symptoms, delayed testing, gave steroids without ruling out infection, continued immunotherapy through serious pneumonitis, or exceeded accepted radiation dose limits, and that failure caused harm.

How long do I have to file a pneumonitis malpractice claim in New York?

Most New York malpractice claims must be filed within two years and six months of the negligent act, though continuous treatment can extend that window. The special discovery rule for missed cancer diagnoses generally doesn’t apply to treatment complications. Wrongful death claims must be filed within two years of death, and public hospital claims require a 90-day notice.